Comerica Bank Sells 13,571 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Comerica Bank lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 54.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,278 shares of the specialty pharmaceutical company's stock after selling 13,571 shares during the period. Comerica Bank's holdings in Collegium Pharmaceutical were worth $323,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in COLL. Nisa Investment Advisors LLC increased its position in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares during the period. AlphaQuest LLC increased its position in Collegium Pharmaceutical by 3.0% during the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after buying an additional 374 shares during the period. Foundry Partners LLC increased its position in Collegium Pharmaceutical by 2.4% during the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock worth $463,000 after buying an additional 381 shares during the period. Gallacher Capital Management LLC increased its position in Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock worth $417,000 after buying an additional 470 shares during the period. Finally, Caprock Group LLC increased its position in Collegium Pharmaceutical by 6.7% during the 4th quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock worth $249,000 after buying an additional 543 shares during the period.

Collegium Pharmaceutical Price Performance

Shares of COLL traded down $0.65 during trading hours on Thursday, hitting $28.82. 224,620 shares of the company were exchanged, compared to its average volume of 428,024. The firm's fifty day moving average is $28.13 and its 200 day moving average is $29.77. The company has a market cap of $926.04 million, a price-to-earnings ratio of 12.42 and a beta of 0.63. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The business had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business's quarterly revenue was up 22.7% compared to the same quarter last year. During the same period last year, the business earned $1.45 earnings per share. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on COLL. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC reissued a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Finally, Piper Sandler reissued a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the transaction, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares of the company's stock, valued at $4,330,048.32. This represents a 20.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock valued at $2,334,994 over the last ninety days. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.